Suppr超能文献

是否应进行心内膜心肌活检以检测心肌炎?一种决策分析方法。

Should endomyocardial biopsy be performed for detection of myocarditis? A decision analytic approach.

作者信息

Hrobon P, Kuntz K M, Hare J M

机构信息

Harvard School of Public Health, Boston, Mass, USA.

出版信息

J Heart Lung Transplant. 1998 May;17(5):479-86.

PMID:9628566
Abstract

BACKGROUND

Performance of endomyocardial biopsy (EMB) to diagnose myocarditis in patients with dilated cardiomyopathy is controversial because of a lack of evidence favoring immunosuppressive therapy. In spite of advances in heart failure treatment, dilated cardiomyopathy carries a poor prognosis, and myocardial inflammation and viral infection are potential therapeutic targets.

METHODS

We used decision analysis to determine the efficacy (5-year risk reduction in mortality or transplantation) that a treatment for myocarditis would require to favor a biopsy-guided approach over conventional therapy. Literature-based estimates included prevalence of myocarditis among patients with dilated cardiomyopathy with or without borderline myocarditis (16% and 11%, respectively); probability of 5-year transplantation-free survival (55%); sensitivity (50% and 63%, respectively), specificity (95.4%), and mortality rate (0.4%) of EMB; side effects resulting in withdrawal of immunosuppressive treatment (4%); and a 6-month mortality rate for immunosuppressive treatment (0.1%). All estimates were varied to determine impact on model results (sensitivity analysis).

RESULTS

A therapy that decreased the rate of death or transplantation by 12.7% and 7.1% for patients without or with borderline myocarditis, respectively, favored EMB. Sensitivity analysis indicated that therapeutic efficacy was influenced by myocarditis prevalence and biopsy-related death, but not by accuracy of biopsy or probability of immunosuppressive therapy side effects. Randomized trials powered to detect 7% and 25% reductions in death and transplantation would require 5790 and 380 end points, respectively.

CONCLUSION

Decreasing the rate of death or transplantation by 7.1% offsets therapy side effects, EMB-related death, and inaccuracies in histologic diagnosis. Prospective randomized trials of treatments for myocarditis may be more feasible during periods of high prevalence or with more sensitive diagnostic techniques.

摘要

背景

由于缺乏支持免疫抑制治疗的证据,经心内膜心肌活检(EMB)诊断扩张型心肌病患者的心肌炎存在争议。尽管心力衰竭治疗取得了进展,但扩张型心肌病的预后仍然很差,心肌炎症和病毒感染是潜在的治疗靶点。

方法

我们使用决策分析来确定心肌炎治疗需要达到何种疗效(5年死亡率或移植率降低),才能支持采用活检引导的方法而非传统治疗。基于文献的估计包括:伴有或不伴有临界性心肌炎的扩张型心肌病患者中心肌炎的患病率(分别为16%和11%);5年无移植生存率(55%);EMB的敏感性(分别为50%和63%)、特异性(95.4%)和死亡率(0.4%);导致免疫抑制治疗中断的副作用(4%);以及免疫抑制治疗的6个月死亡率(0.1%)。对所有估计值进行变化,以确定对模型结果的影响(敏感性分析)。

结果

对于无临界性心肌炎和有临界性心肌炎的患者,分别将死亡或移植率降低12.7%和7.1%的治疗方法更倾向于EMB。敏感性分析表明,治疗效果受心肌炎患病率和活检相关死亡的影响,但不受活检准确性或免疫抑制治疗副作用概率的影响。为检测死亡和移植率分别降低7%和25%而进行的随机试验,分别需要5790个和380个终点。

结论

将死亡或移植率降低7.1%可抵消治疗副作用、EMB相关死亡和组织学诊断的不准确性。在患病率较高或诊断技术更敏感的时期,开展心肌炎治疗的前瞻性随机试验可能更可行。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验